Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452752 | 0.90 | ROCK2 (0.62) | ROCK2GSK3BDYRK1AROCK1USP30 | |
| SCHEMBL19902603 | 0.83 | ROCK2 (0.49) | ROCK2ROCK1USP30SPRKDM4E | |
| SCHEMBL19902613 | 0.82 | ROCK2 (0.48) | ROCK2ROCK1USP30SPRKDM4E | |
| SCHEMBL19902569 | 0.81 | ROCK2 (0.47) | ROCK2ROCK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19902324 | 0.80 | ROCK1 (0.49) | ROCK2ROCK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19902601 | 0.79 | ROCK2 (0.46) | ROCK2ROCK1SPRKDM4EALDH1A1 | |
| SCHEMBL19902418 | 0.79 | ROCK2 (0.45) | ROCK2ROCK1USP30SPRKDM4E | |
| SCHEMBL19902419 | 0.79 | ROCK2 (0.45) | ROCK2ROCK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19902731 | 0.79 | ROCK2 (0.47) | ROCK2ROCK1USP30SPRKDM4E | |
| SCHEMBL19902409 | 0.78 | ROCK2 (0.45) | ROCK2ROCK1SPRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK2 3/4885GSK3B 7/4885DYRK1A 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.